Bisaro, Paul
Type of Action
Process Enforcement
Last Updated
FTC Matter/File Number
061 0182
Case Status
Closed
Displaying 221 - 240 of 333
Novartis AG, In the Matter of (Alcon, Inc)
To settle FTC charges that its proposed acquisition of Alcon, Inc., would be anticompetitive, Novartis AG agreed to sell an injectable eye care drug used in cataract surgery. Novartis and Alcon are the only two U.S. providers of the class of drugs known as injectable miotics, and the FTC alleges that the acquisition would have created a monopoly in injectable miotics. The settlement requires Novartis to sell its drug Miochol-E to Bausch & Lomb, Inc.
Type of Action
Administrative
Last Updated
FTC Matter/File Number
101 0068
Docket Number
C-4296
FTC Files Amicus Brief in Support of Rehearing of Ciprofloxacin "Pay-for-Delay" Case; FTC Approves Final Rule to Inform Consumers About Deposit Institutions That Lack Federal Deposit Insurance
Date
FTC Files Amicus Brief in Support of Rehearing of Ciprofloxacin "Pay-for-Delay" Case The Federal Trade Commission has filed an amicus brief in the U.S. Court of Appeals for the Second Circuit...
Statement by FTC Chairman Jon Leibowitz Regarding Todays Decision by the U.S. Court of Appeals for the Second Circuit in the Ciprofloxacin "Pay-for-Delay" Case
Date
Federal Trade Commission Chairman Jon Leibowitz issued the following statement regarding today’s decision by the U.S. Court of Appeals for the Second Circuit, which invited the plaintiffs in the...
Statement by FTC Chairman Jon Leibowitz Regarding Today’s District Court Decision Denying a Motion to Dismiss the Commission’s Pay-For-Delay Case Against Cephalon Inc.
Date
Today’s decision seems to reflect a growing understanding—first in Congress now in the courts—that brand name drug companies must not be allowed to make pay-offs to their generic competitors to keep...
Statement by FTC Chairman Jon Leibowitz Regarding Continuing Need for Legislation Banning Illegal Pay-for-Delay Drug Settlements
Date
The Federal Trade Commission will continue working on behalf of Americans who are struggling to pay for their health care. According to our economic estimates, consumers would pocket about $3.5...
Statement of Federal Trade Commission Chairman Jon Leibowitz on Ending Pay-for-Delay Drug Settlements, Praises Inclusion in Presidents Health Care Proposal
Date
“When drug companies agree not to compete, consumers lose,” said Federal Trade Commission Chairman Jon Leibowitz. “Ending pay-for-delay settlements will help control drug costs. We’re delighted about...
FTC Approves Final Consent Order in Case of Pfizer Inc. and Wyeth
Date
Following a public comment period, the Federal Trade Commission has approved a final consent order regarding Pfizer Inc.’s recent acquisition of Wyeth, and responses to members of the public who...
Watson Pharmaceuticals, Inc., a corporation, and Robin Hood Holdings Limited, a limited liability company, In the Matter of
The Commission charged that Watson Pharmaceuticals, Inc.’s acquisition of Robin Hood Holdings Limited, owner of Arrow Pharmaceuticals, would have harmed consumers by eliminating future competition for important generic drugs used to treat Parkinson’s disease (cabergoline) and the side effects of chemotherapy (dronabinol). The Commission’s order requires the firms to sell assets related to the two drugs to FTC-approved buyers and to ensure the acquirers have the means to compete effectively in the future.
There is a related federal proceeding and two related administrative proceedings:
Type of Action
Administrative
Last Updated
FTC Matter/File Number
091 0116
Docket Number
C-4276
FTC Chairman, Members of Congress Call for Legislation to End Sweetheart Pay-for-Delay Deals That Keep Generic Drugs Off the Market
Date
Federal Trade Commission Chairman Jon Leibowitz and key members of Congress, including Representative Chris Van Hollen, Chairman Bobby Rush, and Representative Mary Jo Kilroy, today renewed their call...
FTC Order Ensures Future Competition for Parkinsons and Chemotherapy Drugs That Watsons Acquisition of Arrow Would Have Eliminated
Date
The Federal Trade Commission today announced a proposed consent order settling charges that Watson Pharmaceuticals, Inc.’s acquisition of Robin Hood Holdings Limited, owner of Arrow Pharmaceuticals...
FTC Order Restores Competition Lost Through Schering-Plough's Acquisition of Merck
Date
Merck & Co., Inc. must sell its interest in Merial Limited, an animal health joint venture with Sanofi-Aventis S.A., and Schering-Plough must sell its assets related to significant drugs for nausea...
Statement of FTC Chairman Jon Leibowitz Regarding the Senate Judiciary Committee's Passage of the Preserve Access to Affordable Generics Act (S. 369)
Date
By taking this action, the Committee clearly recognizes the very real danger that these sweetheart deals pose to Americans struggling to pay their medical bills. Consumers must wait – sometimes years...
FTC Order Prevents Anticompetitive Effects from Pfizers Acquisition of Wyeth
Date
The Federal Trade Commission today announced a settlement resolving its extensive investigation of Pfizer Inc.’s proposed $68 billion acquisition of Wyeth and requiring significant divestitures to...
Statement by FTC Chairman Jon Leibowitz on Adoption of the Pay for Delay Amendment to the Americas Affordable Health Choices Act of 2009 by the House Energy and Commerce Committee
Date
I commend the House Energy and Commerce Committee for adopting the Protecting Consumer Access to Generic Drugs Act (H.R.1706) as an amendment to the omnibus health reform legislation. If enacted into...
FTC Issues Interim Report on "Authorized Generic" Drugs
Date
The Federal Trade Commission today issued “Authorized Generics: An Interim Report,” which presents the first set of results from a study conducted to examine the short-term and long-term effects of...
FTC Chairman Leibowitz: Eliminating Pay-for-Delay Pharmaceutical Settlements Would Save Consumers $3.5 Billion Annually
Date
In a speech today before the Center for American Progress in Washington, D.C., Federal Trade Commission Chairman Jon Leibowitz said that an internal FTC analysis projects that stopping collusive “pay...
CSL Limited, a corporation, and Cerberus-Plasma Holdings, LLC, In the Matter of
The FTC authorized a lawsuit to block CSL Limited’s proposed $3.1 billion acquisition of Talecris Biotherapeutics Holdings Corporation, charging that the deal would would substantially reduce competition in the U.S. markets for four plasma-derivative protein therapies – Immune globulin (Ig), Albumin, Rho-D, and Alpha-1. These therapies are used to treat patients suffering from illnesses such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, alpha-1 antitrypsin disease, and hemolytic disease of the newborn. In approving the administrative complaint seeking to block the deal, the Commission also authorized the staff to seek a preliminary injunction in federal district court in Washington, D.C., to stop the transaction pending completion of the administrative trial. Following the FTC's lawsuit to block the transaction, CSL Limited announced that it would not proceed with its proposed acquisition.
Type of Action
Administrative
Last Updated
FTC Matter/File Number
081 0255
Docket Number
9337
FTC Testifies on "Competition Issues and Follow-on Biologic Drugs"
Date
Testifying today on behalf of the Federal Trade Commission before the Subcommittee on Health of the U.S. House of Representatives Energy and Commerce Committee, Commissioner Pamela Jones Harbour...
FTC Releases Report on Follow-on Biologic Drug Competition
Date
The Federal Trade Commission today released a report entitled “Follow-on Biologic Drug Competition”which examines whether the price of biologic drugs – products manufactured using living tissues and...
Displaying 221 - 240 of 333